Risk stratification, prevention and occurrence of refeeding syndrome in adults using a computer-based tool: a prospective cohort study

Abstract Background: Organ/space surgical site infection (organ/space SSI) is one of the serious postoperative complications, closely related to a poor prognosis. Few studies have attempted to design risk scoring systems for patients with digestive system cancer. This study aimed to develop a simple and practical risk stratification score for these patients to identify a priori risk of organ/space SSI.Methods: This prospective cohort study was based on two prospective studies (NCT02756910, ChiCTR-IPR-17011099), including patients undergoing elective radical resection of digestive system cancer. Logistic regression analysis was used to identify the determinant variables. The incidence of organ/space SSI stratified over perioperative factors was compared and compounded in a risk score.Results: Among the 839 patients, 51 developed organ/space SSI (6.1%) within 30 days after surgery. Patients undergoing gastrectomy (OR=8.466, 95% CI: 2.728-26.270, P<0.001), colorectal resection (OR=11.180, 95% CI: 3.921-31.881, P<0.001) and pancreatoduodenectomy (OR=9.054, 95% CI: 3.329-24.624, P<0.001) with an anaesthesia time > 4 h (OR=2.335, 95% CI: 1.035-5.271, P=0.041) and prolonged intensive care unit (ICU) stays > 24 h (OR=4.243, 95% CI: 1.715-10.498, P=0.002) had a significantly higher risk of organ/space SSI. These risk factors (procedure type, anaesthesia time, prolonged ICU stays) were also associated with an increase in organ/space SSI rates based on a compounded score (P<0.001). Comparisons with the overall population revealed that patients with 0 or 1 risk factor (n=602) had an organ/space SSI rate of 2.8% (RR=0.197, 95% CI: 0.112-0.345), those with 2 risk factors (n=223) had an organ/space SSI rate of 13.0% (RR=3.641; 95% CI: 2.138-6.202), and those with 3 risk factors (n=14) had an organ/space SSI rate of 35.7% (RR=6.405, 95% CI: 3.005-13.653).Conclusion: The risk stratification score in this study provides a simple and practical tool to stratify patients with digestive system cancer so that the relative risk of developing postoperative organ/space SSIs can be predicted.Trial Registration: This study was based on one randomized controlled trial (NCT02756910) registered at ClinicalTrials.gov on April 29, 2016 and one prospective cohort study (ChiCTR-IPR-17011099) registered at the Chinese Clinical Trial Registry on April 9, 2017.

Download Full-text

Prospective cohort study of the predictive value of inflammatory biomarkers over clinical variables in children and young people with cancer presenting with fever and neutropenia

F1000Research ◽

10.12688/f1000research.73075.1 ◽

2021 ◽

Vol 10 ◽

pp. 1070

Author(s):

Bob Phillips

Keyword(s):

Cohort Study ◽

Risk Stratification ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Serum Biomarkers ◽

Inflammatory Biomarkers ◽

Organ Support ◽

Improve Risk Stratification ◽

C Statistic ◽

Poor Individual

Introduction Fever during chemotherapy induced neutropenia is a common and potentially life-threatening complication of the treatment of childhood cancer. Predictions of poor outcome could be enhanced by incorporating serum biomarkers of inflammation at presentation and reassessment. Methods A prospective cohort study was conducted of children under 18 years old, being treated for cancer or a cancer-like condition, who presented with fever (≥ 38.0°C) and neutropenia (neutrophil count < 0.5*109/L). Clinical features were recorded, along with three experimental inflammatory biomarkers: procalcitonin (PCT), interleukin-6 (IL-6) and interleukin-8 (IL-8). Outcomes included serious medical complications (SMC): any infection related mortality, critical care and organ support, severe sepsis, septic shock, significant microbiologically defined infection, or radiologically confirmed pneumonia. Results Biomarker assessments were undertaken in 43 episodes of fever and neutropenia, from 31 patients aged between four months and 17 years old (median six years): 20 were female and 22 had acute leukaemia. Five episodes of SMC were noted. PCT, IL-6 and IL-8 had poor individual discriminatory ability (C-statistic 0.48 to 0.60) and did not add to the value of clinical risk stratification tools. Insufficient data were collected to formally assess the value of repeated assessments. Conclusions Incorporating serum biomarkers of inflammation at presentation of episodes of fever with neutropenia in childhood does not clearly improve risk stratification. Repeated assessments over time may be of value.

Download Full-text